Lexicon Pharmaceuticals (LXRX) Intangibles (2010 - 2020)

Lexicon Pharmaceuticals (LXRX) has 11 years of Intangibles data on file, last reported at $18.8 million in Q2 2020.

• Quarterly Intangibles fell 61.75% year-over-year to $18.8 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $18.8 million (down 61.75% YoY) and the FY2019 annual result came in at $19.7 million, down 60.66% from the prior year.
• Intangibles fell to $18.8 million in Q2 2020 per LXRX's latest filing, from $19.3 million in the prior quarter.
• Across five years, Intangibles topped out at $53.4 million in Q1 2016 and bottomed at $18.8 million in Q2 2020.
• The 5-year median for Intangibles is $50.8 million (2018), against an average of $43.1 million.
• The widest annual swing landed in 2018, when Intangibles jumped 108.28%; it then tumbled 61.75% in 2020.
• Tracing LXRX's Intangibles over 5 years: stood at $53.4 million in 2016, then dropped by 2.76% to $51.9 million in 2017, then dropped by 3.4% to $50.1 million in 2018, then sank by 60.66% to $19.7 million in 2019, then retreated by 4.48% to $18.8 million in 2020.
• Per Business Quant, the three latest LXRX Intangibles figures stand at $18.8 million (Q2 2020), $19.3 million (Q1 2020), and $19.7 million (Q4 2019).

Peer Comparison